Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1908-1909 in Allergic Conjunctivitis with Cat Allergy
NCT06602726Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of freneslerbart, mevonlerbart in allergic conjunctivitis (AC), sponsored by Regeneron Pharmaceuticals. Started Nov 2024; status: completed.
02
Drugs
freneslerbartmevonlerbart
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT06602726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602726.